MUSASHI‐2 confers resistance to third‐generation EGFR‐tyrosine kinase inhibitor osimertinib in lung adenocarcinoma

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are effective in patients with non–small‐cell lung cancer (NSCLC) harboring EGFR mutations. However, due to acquired resistance to EGFR‐TKIs, even patients on third‐generation osimertinib have a poor prognosis. Resistance mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Yiming, Reheman, Takeuchi, Yasuto, Nishimura, Tatsunori, Li, Mengjiao, Wang, Yuming, Meguro‐Horike, Makiko, Kohno, Takashi, Horike, Shin‐ichi, Nakata, Asuka, Gotoh, Noriko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409425/
https://www.ncbi.nlm.nih.gov/pubmed/34145929
http://dx.doi.org/10.1111/cas.15036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409425/
https://www.ncbi.nlm.nih.gov/pubmed/34145929
http://dx.doi.org/10.1111/cas.15036

Ejemplares similares